Medical device development firm Ximedica recently expanded its West Coast capabilities with the acquisition of Los Gatos, Calif.-based Accel Biotech.
The deal expands Ximedica’s design and development reach into in vitro diagnostics, life science laboratory instruments and disposables and will complement its 2015 addition of Bridge Design of San Francisco.
“Ximedica brings the regulated systems, procedures, discipline and expertise to complement and enhance Accel Biotech’s wide range of complex technologies including optics, various detection methods, motion control/robotics, fluid management and consumables/cartridges. These combined strengths will bring high value to our clients, offering a risk averse and cost effective development approach and a depth of expertise second to none,” said Randall Barko, Ximedica’s president and CEO, in a news release.
Accel Biotech will continue operating out of its existing Silicon Valley facility and will now have an East Coast presence through Ximedica.
Ximedica, based in Providence, R.I., is a ISO 13485-certified and FDA-registered product development company. It also has offices in Hong Kong, Minneapolis, and San Francisco.
Ximedica announced in August 2015 that it had bought Bridge Design, a medical technology development firm in San Francisco.
Private equity firm SV Life Sciences of Boston acquired a majority stake in Ximedica in November 2014.